Who is sponsoring NCT04888442?

NCT04888442 is sponsored by Chongqing Precision Biotech Co., Ltd.

What drugs are being tested in NCT04888442?

Interventions in NCT04888442: pCAR-19B cells.

What condition does NCT04888442 study?

NCT04888442 studies Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia.

Is NCT04888442 still recruiting?

NCT04888442 is currently status unknown. Last updated 17 May 2021.

Last reviewed 2021-05-17 · How we verify

NCT04888442

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL

Status unknown Phase 1 Last updated 17 May 2021

What this trial tests

Phase 1 trial testing pCAR-19B cells in Acute Lymphoblastic Leukemia, in Relapse in 18 participants. Status unknown.

Timeline

26 October 2020

Primary endpoint
30 January 2022

28 March 2022

Quick facts

Lead sponsor	Chongqing Precision Biotech Co., Ltd
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	26 October 2020
Primary completion	30 January 2022
Estimated completion	28 March 2022
Sites	1 location across China

Drugs / interventions tested

pCAR-19B cells — full drug profile →

Conditions studied

Acute Lymphoblastic Leukemia, in Relapse — all drugs for Acute Lymphoblastic Leukemia, in Relapse →
Refractory Acute Lymphoblastic Leukemia — all drugs for Refractory Acute Lymphoblastic Leukemia →

Sponsor

Chongqing Precision Biotech Co., Ltd — full company profile →

Who can join

Adults 22 to 70, any sex, with Acute Lymphoblastic Leukemia, in Relapse or Refractory Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in adults with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Trial watch: chemotherapy-induced immunogenic cell death in oncology.
Sprooten J, Laureano RS, Vanmeerbeek I, Govaerts J, et al · · 2023 · cited 59× · PMID 37284695 · DOI 10.1080/2162402x.2023.2219591
Infection complications in febrile chimeric antigen receptor (CAR)-T recipients during the peri-CAR-T cell treatment period examined using metagenomic next-generation sequencing (mNGS).
Nie J, Yang L, Huang L, Gao L, et al · · 2022 · cited 16× · PMID 35032364 · DOI 10.1002/cac2.12260

Verify or expand the search:

Other trials of pCAR-19B cells

Trials testing the same drug.

NCT05334823 — A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents · Phase 2 · recruiting
NCT04888468 — Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents · Phase 1 · completed

Other recruiting trials for Acute Lymphoblastic Leukemia, in Relapse

Currently open trials in the same condition.

NCT06326008 — Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri · Phase 1 · recruiting
NCT05745714 — HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Rela · Phase 1, PHASE2 · recruiting
NCT07070323 — A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/R · Phase 1, PHASE2 · recruiting
NCT06213636 — Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). · Phase 1, PHASE2 · recruiting
NCT06316856 — CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies · Phase 1, PHASE2 · recruiting

Other Chongqing Precision Biotech Co., Ltd trials

Trials by the same sponsor.

NCT07181720 — CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07184450 — Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases · Phase 1 · recruiting
NCT07239323 — In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies · Phase 1 · recruiting
NCT06892145 — Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04888442 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chongqing Precision Biotech Co., Ltd
Last refreshed: 17 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04888442.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing